Results 201 to 210 of about 3,117,221 (377)

How do insurance companies manage reserves? Evidence from reserve errors across lines of business and accident years

Jing Rong Goh, Shinichi Kamiya, Pingyi Lou   +2 more
openalex   +1 more source

Factors Influencing Professionalism of Nurses in Community Based Non-life Insurance Company in South Korea

, 2019
En-Ju Song, Bo Young Kim
openalex   +1 more source

Optimal dividends for a NatCat insurer in the presence of a climate tipping point

Canadian Journal of Statistics, EarlyView.
Abstract We study optimal dividend strategies for an insurance company facing natural catastrophe claims, anticipating the arrival of a climate tipping point after which the claim intensity and/or the claim size distribution of the underlying risks deteriorates irreversibly.
Hansjörg Albrecher, Pablo Azcue, Nora Muler   +2 more
wiley   +1 more source

Basket cliquet options pricing with a dynamic dependence structure and stochastic interest rates [PDF]

Insurance Markets and Companies, 2013
Giovanni Masala
doaj  

A hybrid model based on CNN-LSTM for assessing the risk of increasing claims in insurance companies. [PDF]

PeerJ Comput Sci
Gamaleldin W, Attayyib O, Alnfiai MM, Alotaibi FA, Ming R.   +4 more
europepmc   +1 more source

Effect of Behavioural Biases on Tactical Asset Allocation in Insurance Companies in Mombasa Town, Kenya

, 2019
Ogilo Fredrick, Benard Nyarige
openalex   +2 more sources

Discussion on Internal Control of Insurance Companies

, 2023
Chunzhen Yang
openalex   +2 more sources

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

Clinical Pharmacology &Therapeutics, EarlyView.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko, Philip C. M. Au, Michael Chun‐Yuan Cheng, Ching‐Lung Cheung, Ahhyung Choi, Miyuki Hsing‐Chun Hsieh, Han Eol Jeong, Edward Chia‐Cheng Lai, Brian Meng‐Hsun Li, Kenneth K. C. Man, Jeremy A. Rassen, Daniel Hsiang‐Te Tsai, Shirley V. Wang, Ian C. K. Wong, Ju‐Young Shin, Sohee Park   +15 more
wiley   +1 more source

Formalization of the “risk” category during the realization of reinsurance operations on the basis of the economic and mathematical apparatus [PDF]

Insurance Markets and Companies, 2011
Olha Kozmenko, Olha Kuzmenko
doaj  

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source